

ALLIED HEALTHCARE PRODUCTS INC

Form 8-K

November 13, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

November 9, 2017

**ALLIED HEALTHCARE PRODUCTS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**0-19266**

**25-1370721**

(State or Other Jurisdiction (Commission (IRS Employer

of Incorporation)

File Number) Identification No.)

**1720 Sublette Avenue, St. Louis, Missouri 63110**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

**(314) 771-2400**

Not applicable

**(Former name or former address, if changed since last report)**

Edgar Filing: ALLIED HEALTHCARE PRODUCTS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**ITEM 5.07. Submission of Matters to a Vote of Security Holders.**

The annual meeting of the stockholders of Allied Healthcare Products, Inc. (the “Company”) was held on November 9, 2017. Proxies were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934. There was no solicitation in opposition to management’s nominees for Directors. The voting results are noted below.

**ELECTION OF DIRECTORS**

All nominees for Directors were elected with the following votes cast:

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Judith T. Graves	2,213,834	22,506	1,252,284
Joseph E. Root	2,213,785	22,556	1,252,284
William A. Peck	2,209,766	26,574	1,252,284
Earl R. Refsland	2,214,739	21,426	1,252,284
John D. Weil	2,199,698	35,458	1,252,284

Agenda Item 2, concerning the ratification of the appointment of RubinBrown LLP as the Company’s independent registered public accounting firm for fiscal 2018 was approved by the stockholders with the following votes cast:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
3,423,657	54,520	10,471	0

Agenda Item 3, an advisory (non-binding) vote to approve our executive compensation was approved by the stockholders with the following votes cast:

<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
2,174,992	28,011	33,361	1,252,284

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALLIED HEALTHCARE  
PRODUCTS, INC.

Date: November 13, 2017 By: /s/ Daniel C. Dunn  
Daniel C. Dunn  
Chief Financial Officer